12 December 2025
Lilly's Inluriyo™ Shows Efficacy in ER+, HER2- Breast Cancer
Inluriyo™ improves survival in ER+, HER2- breast cancer, both alone and with abemaciclib, extending time to chemotherapy and showing durable benefits across patient groups.
